
Ultralife (ULBI) Stock Forecast & Price Target
Ultralife (ULBI) Analyst Ratings
Bulls say
Ultralife Corp experienced a strong top-line sales growth of 23.4% year-over-year, driven by record medical sales and significant increases in both Government and Defense (G&D) and Commercial segments, at 28.8% and 20.2% respectively. The company reported an improved gross profit margin of 25.6%, up from 22.4% year-over-year, reflecting enhanced operational efficiency amid the easing of supply chain constraints. Additionally, the positive cash flow from operations has enabled the company to initiate debt repayment, reducing interest burdens and positioning it favorably for continued growth as it launches new products and integrates the recent acquisition of ElectroChem.
Bears say
Ultralife Corp reported third-quarter revenues of $35.7 million, a decrease from $39.5 million year-over-year and falling short of the $43 million estimate. The company's adjusted EBITDA of $1.9 million also significantly underperformed expectations, being lower than the forecasted $5.2 million due to weaker top-line results. Contributing to this negative outlook, Ultralife faced supply chain challenges and delays in fulfilling large customer orders across both its Communications Systems and Battery & Energy Products segments.
This aggregate rating is based on analysts' research of Ultralife and is not a guaranteed prediction by Public.com or investment advice.
Ultralife (ULBI) Analyst Forecast & Price Prediction
Start investing in Ultralife (ULBI)
Order type
Buy in
Order amount
Est. shares
0 shares